申请人:Helmholtz-Zentrum für Infektionsforschung GmbH
公开号:EP3818045A1
公开(公告)日:2021-05-12
PqsR INVERSE AGONISTS
申请人:HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH
公开号:US20210353606A1
公开(公告)日:2021-11-18
The present invention relates to a compound according to general formula (I), which acts as an inhibitor of PqsR (the currently only known receptor for the
Pseudomonas
Quinolone Signal (PQS)); to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament, e.g. the use in the treatment or prophylaxis of a bacterial infection, especially a
Pseudomonas aeruginosa
or
Burkholderia
infection.
[EN] PqsR INVERSE AGONISTS<br/>[FR] AGONISTES INVERSES DE PQSR
申请人:HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH
公开号:WO2020007938A1
公开(公告)日:2020-01-09
The present invention relates to a compound according to general formula (I), which acts as an inhibitor of PqsR (the currently only known receptor for the Pseudomonas Quinolone Signal (PQS)); to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament, e.g. the use in the treatment or prophylaxis of a bacterial infection, especially a Pseudomonas aeruginosa or Burkholderia infection.